In 2004, with regard to preclinical and clinical safety assessmentsfor PPAR agonists, the Food and Drug Administration recommended that, due to the prevalence of positive tumor findings of PPARagonists, two-year carcinogenicity studies on mice and rats are required [66]. The gene discussed is PPARA; the disease is neoplasm.